The process might take six months and the final assessment on the safety and the anti-bodies produced would be made by the safety board.
Three volunteers were administered“Covaxin”, the corona vaccine of Bharat Biotech, at Post-Graduate Institute (PGI) of Medical Sciences in Rohtak on Friday, as part of the first phase of clinical trial on the humans. All three tolerated it well without any initial adverse effects.
Senior Professor and Head, department of Pulmonary & Critical Care Medicine, Dhruva Chaudhry, also the co-principal investigator, toldThe Hinduover phone that the three volunteers were short-listed out of the total eight after health checks to ensure proper liver function and absence of infection and were administered the vaccine.
“All three tolerated it well. There were no complaints. We observed them for two hours before releasing them. The immediate component of allergic reaction has been taken care of. We will now look for any soreness at the local site over the next 24-48 hours,” said Dr. Dhruv, taking care of clinical aspect of the process at the institute. Dr. Savita Verma, the principal investigator, takes care of logistics and control, and Dr. Rakesh Verma is responsible for the vaccination aspects of the process.
Dr. Chaudary said the vaccine had been tested successfully on the animals for safety and response and the process had not entered the first phase of clinical trial on the humans. He said the process might take six months and the final assessment on the safety and the anti-bodies produced would be made by the safety board.
Haryana Health Minister Anil Vij also tweeted about the trial: “Human trial with Corona vaccine (COVAXIN)of Bharat Biotech started at PGI Rohtak today. Three subjects were enrolled today. All have tolerated the vaccine very well. There were no adverse efforts (sic).”
You have reached your limit for free articles this month.
To get full access, please subscribe.
Already have an account ?Sign in
Show Less Plan
Start your 14 days trial now.Sign Up
Subscription Benefits Include
Find mobile-friendly version of articles from the day’s newspaper in one easy-to-read list.
Move smoothly between articles as our pages load instantly.
Enjoy reading as many articles as you wish without any limitations.
A one-stop-shop for seeing the latest updates, and managing your preferences.
A select list of articles that match your interests and tastes.
We brief you on the latest and most important developments, three times a day.
*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.
A letter from the Editor
We have been keeping you up-to-date with information on the developments in India and the world that have a bearing on our health and wellbeing, our lives and livelihoods, during these difficult times. To enable wide dissemination of news that is in public interest, we have increased the number of articles that can be read free, and extended free trial periods. However, we have a request for those who can afford to subscribe: please do. As we fight disinformation and misinformation, and keep apace with the happenings, we need to commit greater resources to news gathering operations. We promise to deliver quality journalism that stays away from vested interest and political propaganda.
A letter from the Editor
Your support for our journalism is invaluable. It’s a support for truth and fairness in journalism. It has helped us keep apace with events and happenings.
The Hindu has always stood for journalism that is in the public interest. At this difficult time, it becomes even more important that we have access to information that has a bearing on our health and well-being, our lives, and livelihoods. As a subscriber, you are not only a beneficiary of our work but also its enabler.
We also reiterate here the promise that our team of reporters, copy editors, fact-checkers, designers, and photographers will deliver quality journalism that stays away from vested interest and political propaganda.
Subscribe to Morning Filter & Evening Wrap newsletter
Please enter a valid email address.
- Comments will be moderated by The Hindu editorial team.
- Comments that are abusive, personal, incendiary or irrelevant cannot be published.
- Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not ‘the’, n is not ‘and’).
- We may remove hyperlinks within comments.
- Please use a genuine email ID and provide your name, to avoid rejection.
Printable version | Jul 17, 2020 4:00:22 PM | https://www.thehindu.com/news/national/bharat-bi